Ocugen Analyst Ratings
Ocugen Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/23/2023 | 1140.08% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 05/08/2023 | 892.06% | Chardan Capital | $3.5 → $4 | Maintains | Buy |
| 04/17/2023 | 1140.08% | HC Wainwright & Co. | → $5 | Reiterates | → Buy |
| 04/14/2023 | 768.06% | Chardan Capital | → $3.5 | Maintains | Buy |
| 03/01/2023 | 768.06% | Chardan Capital | → $3.5 | Upgrades | Neutral → Buy |
| 03/01/2023 | 644.05% | Mizuho | $5 → $3 | Maintains | Buy |
| 03/01/2023 | 1140.08% | HC Wainwright & Co. | $6 → $5 | Reiterates | → Buy |
| 08/23/2022 | 1140.08% | Mizuho | → $5 | Initiates Coverage On | → Buy |
| 08/15/2022 | 1388.1% | HC Wainwright & Co. | $7 → $6 | Maintains | Buy |
| 06/15/2022 | 1884.13% | Roth Capital | → $8 | Reinstates | → Buy |
| 06/02/2022 | 1016.07% | Cantor Fitzgerald | → $4.5 | Initiates Coverage On | → Overweight |
| 05/12/2022 | 1636.11% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 02/28/2022 | 1884.13% | HC Wainwright & Co. | $10 → $8 | Maintains | Buy |
| 06/11/2021 | 1388.1% | Roth Capital | $10 → $6 | Downgrades | Buy → Neutral |
| 06/11/2021 | 2380.16% | HC Wainwright & Co. | $12 → $10 | Maintains | Buy |
| 05/07/2021 | 2628.17% | Cantor Fitzgerald | $15 → $11 | Downgrades | Overweight → Neutral |
| 03/03/2021 | 3620.24% | Cantor Fitzgerald | $4 → $15 | Maintains | Overweight |
| 02/09/2021 | 3124.21% | Chardan Capital | $0.7 → $13 | Downgrades | Buy → Neutral |
| 02/04/2021 | 1016.07% | HC Wainwright & Co. | → $4.5 | Upgrades | Neutral → Buy |
| 11/17/2020 | 148.02% | Roth Capital | → $1 | Initiates Coverage On | → Buy |
| 10/09/2020 | 148.02% | Cantor Fitzgerald | → $1 | Initiates Coverage On | → Overweight |
| 06/03/2020 | 73.61% | Chardan Capital | $2 → $0.7 | Maintains | Buy |
| 06/01/2020 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 12/20/2019 | — | HC Wainwright & Co. | Initiates Coverage On | → Buy | |
| 11/27/2019 | 396.03% | Chardan Capital | → $2 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/23/2023 | 1140.08% | HC Wainwright & Co. | → 5 美元 | 重申 | 購買 → 購買 |
| 05/08/2023 | 892.06% | 查丹資本 | 3.5 美元 → 4 美元 | 維護 | 購買 |
| 04/17/2023 | 1140.08% | HC Wainwright & Co. | → 5 美元 | 重申 | → 購買 |
| 04/14/2023 | 768.06% | 查丹資本 | → 3.5 美元 | 維護 | 購買 |
| 03/01/2023 | 768.06% | 查丹資本 | → 3.5 美元 | 升級 | 中性 → 買入 |
| 03/01/2023 | 644.05% | 瑞穗 | 5 美元 → 3 美元 | 維護 | 購買 |
| 03/01/2023 | 1140.08% | HC Wainwright & Co. | 6 美元 → 5 美元 | 重申 | → 購買 |
| 2022 年 8 月 23 日 | 1140.08% | 瑞穗 | → 5 美元 | 啓動覆蓋開啓 | → 購買 |
| 08/15/2022 | 1388.1% | HC Wainwright & Co. | 7 美元 → 6 美元 | 維護 | 購買 |
| 06/15/2022 | 1884.13% | 羅斯資本 | → 8 美元 | 恢復 | → 購買 |
| 06/02/2022 | 1016.07% | 坎託·菲茨傑拉德 | → 4.5 美元 | 啓動覆蓋開啓 | → 超重 |
| 2022 年 12 月 5 日 | 1636.11% | HC Wainwright & Co. | 8 美元 → 7 美元 | 維護 | 購買 |
| 02/28/2022 | 1884.13% | HC Wainwright & Co. | 10 美元 → 8 美元 | 維護 | 購買 |
| 06/11/2021 | 1388.1% | 羅斯資本 | 10 美元 → 6 美元 | 降級 | 買入 → 中性 |
| 06/11/2021 | 2380.16% | HC Wainwright & Co. | 12 美元 → 10 美元 | 維護 | 購買 |
| 05/07/2021 | 2628.17% | 坎託·菲茨傑拉德 | 15 美元 → 11 美元 | 降級 | 超重 → 中性 |
| 03/03/2021 | 3620.24% | 坎託·菲茨傑拉德 | 4 美元 → 15 美元 | 維護 | 超重 |
| 02/09/2021 | 3124.21% | 查丹資本 | 0.7 美元 → 13 美元 | 降級 | 買入 → 中性 |
| 2021 年 4 月 2 日 | 1016.07% | HC Wainwright & Co. | → 4.5 美元 | 升級 | 中性 → 買入 |
| 2020 年 11 月 17 日 | 148.02% | 羅斯資本 | → 1 美元 | 啓動覆蓋開啓 | → 購買 |
| 2020 年 9 月 10 日 | 148.02% | 坎託·菲茨傑拉德 | → 1 美元 | 啓動覆蓋開啓 | → 超重 |
| 06/03/2020 | 73.61% | 查丹資本 | $2 → 0.7 美元 | 維護 | 購買 |
| 2020 年 1 月 6 日 | — | HC Wainwright & Co. | 降級 | 買入 → 中性 | |
| 12/20/2019 | — | HC Wainwright & Co. | 啓動覆蓋開啓 | → 購買 | |
| 11/27/2019 | 396.03% | 查丹資本 | → 2 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for Ocugen (OCGN)?
Ocugen（OCGN）的目標價格是多少？
The latest price target for Ocugen (NASDAQ: OCGN) was reported by HC Wainwright & Co. on August 23, 2023. The analyst firm set a price target for $5.00 expecting OCGN to rise to within 12 months (a possible 1140.08% upside). 7 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年8月23日公佈了Ocugen（納斯達克股票代碼：OCGN）的最新目標股價。該分析公司將目標股價定爲5.00美元，預計OCGN將在12個月內上漲至1140.08％（可能上漲1140.08％）。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Ocugen (OCGN)?
Ocugen (OCGN) 的最新分析師評級是多少？
The latest analyst rating for Ocugen (NASDAQ: OCGN) was provided by HC Wainwright & Co., and Ocugen reiterated their buy rating.
HC Wainwright & Co. 對Ocugen（納斯達克股票代碼：OCGN）的最新分析師評級由HC Wainwright & Co. 提供，Ocugen重申了買入評級。
When is the next analyst rating going to be posted or updated for Ocugen (OCGN)?
Ocugen（OCGN）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ocugen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ocugen was filed on August 23, 2023 so you should expect the next rating to be made available sometime around August 23, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與Ocugen的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Ocugen的最後一次評級是在2023年8月23日提交的，因此你應該預計下一個評級將在2024年8月23日左右公佈。
Is the Analyst Rating Ocugen (OCGN) correct?
分析師評級 Ocugen (OCGN) 是否正確？
While ratings are subjective and will change, the latest Ocugen (OCGN) rating was a reiterated with a price target of $0.00 to $5.00. The current price Ocugen (OCGN) is trading at is $0.40, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但重申了最新的Ocugen（OCGN）評級，目標股價爲0.00美元至5.00美元。Ocugen（OCGN）的當前交易價格爲0.40美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。